GlassScriptPhysician profile
Ashley M House
NPI 1013254358
$13,958.55
in general payments reported to CMS, 2019-2025
46 companies · $2,519 in 2025
The $2,519 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,439 · 2022: $3,218 · 2023: $3,065 · 2024: $2,718 · 2025: $2,519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,301.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,891.86 | 2021-2025 | Freestyle Libre |
| Novo Nordisk INC | $1,538.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,484.07 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $1,048.54 | 2021-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $966.58 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $876.04 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Bayer Healthcare Pharmaceuticals INC. | $782.45 | 2021-2025 | |
| Amgen INC. | $692.20 | 2021-2025 | Evenity, Prolia, Repatha |
| Corcept Therapeutics | $607.24 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $438.01 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.78 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $317.54 | 2021-2023 | Farxiga |
| Averitas Pharma INC. | $315.10 | 2023-2025 | Qutenza |
| Radius Health, INC. | $301.35 | 2021-2025 | |
| Insulet Corporation | $237.54 | 2021-2025 | Omnipod |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $235.73 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $202.39 | 2021-2022 | |
| Abbvie INC. | $183.77 | 2021-2025 | |
| Becton, Dickinson and Company | $157.80 | 2022 | |
| Ibsa Pharma INC. | $149.24 | 2021-2024 | Tirosint, Licart, Tirosint |
| Zealand Pharma US, INC. | $142.63 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $102.47 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $78.25 | 2024-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $78.23 | 2023-2025 | Yorvipath |
| Embecta Corp. | $77.51 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Novartis Pharmaceuticals Corporation | $69.71 | 2023-2025 | |
| Clarus Therapeutics INC. | $63.05 | 2021 | |
| Esperion Therapeutics, INC. | $60.11 | 2021-2025 | Nexletol |
| Lifescan, INC. | $53.36 | 2021-2022 | |
| Mannkind Corporation | $47.01 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $41.36 | 2021-2024 | Crysvita |
| Sequel Med Tech, LLC | $41.20 | 2025 | Twiist |
| Regeneron Healthcare Solutions, INC. | $38.94 | 2023-2024 | Evkeeza |
| Rochester Medical Corporation | $29.22 | 2021 | |
| Kyowa Kirin, INC. | $25.65 | 2025 | |
| Alvogen INC | $23.54 | 2025 | Teriparatide |
| Nevro Corp. | $22.85 | 2024 | Senza |
| Madrigal Pharmaceuticals | $22.78 | 2025 | Rezdiffra |
| Almatica Pharma LLC | $21.51 | 2025 | Teriparatide |
| Vistapharm, INC. | $18.11 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $17.80 | 2024 | Baqsimi |
| Renalytix Ai, INC. | $14.31 | 2022 | |
| Amarin Pharma, INC. | $13.11 | 2021 | |
| Vifor Pharma, INC. | $12.16 | 2021 | |
| Amneal Pharmaceuticals LLC | $11.17 | 2021 | |
| Genentech USA, INC. | $7.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley House listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.